Pain is the most significant barrier to sports participation and injury recovery. Therefore, pain management is often the focus of acute injury management. Nella Grilo reviews the evidence on the efficacy and safety of topical NSAIDs in treating musculoskeletal pain.
Tennis - Sloane Stephens of the U.S. in action during her first-round match against Clara Burel of France. REUTERS/Shannon Stapleton
Musculoskeletal conditions affecting bones, joints, and muscles are the leading causes of global disability, impacting approximately 1.71 billion(1). Common issues include low back pain, OA, rheumatoid arthritis (RA), gout, and lupus. The prevalence of musculoskeletal pain in adults ranges from 18% to 80%, exacerbated by factors like population growth, urbanization, and increased life expectancy(2). Clinicians commonly use non-steroidal anti-inflammatory drugs (NSAIDs) for pain management, but they can cause gastrointestinal, cardiovascular, and renal issues when taken orally. In the USA, 65.4% of osteoarthritis (OA) patients and 56.1% of chronic low back pain patients use NSAIDs, while the UK saw 10.36 million prescriptions for oral NSAIDs in 2020(3). Topical NSAIDs are becoming increasingly popular, particularly among high-risk patients, as they provide localized pain relief with minimal systemic exposure(4).
Painful musculoskeletal conditions, such as low back pain and OA, are common worldwide. These conditions may be age-related, affecting more than half of adults over 60 and rare in children. In the US, the 2009 National Health Interview Survey found that 28% of people reported lower back pain, 19% knee pain, 15% neck pain, and 8% hand pain over three months. A 2020 cross-sectional survey of over 52,000 individuals across 14 countries revealed that half experienced significant pain impacting their lives(5).
The Global Burden of Disease Project measures health loss using disability-adjusted life years (DALYs) and years lived with disability (YLDs). The 2010 survey first highlighted musculoskeletal pain as a leading cause of global disability. By 2016, low back and neck pain ranked third in total DALYs, behind only ischemic heart disease and cerebrovascular disease. In 2017, musculoskeletal conditions accounted for 18% of all YLDs globally, with a 19.9% increase in YLDs from 2000 to 2017. Musculoskeletal pain significantly affects emotional wellbeing in 40% and quality of life in 59% of individuals. All this emphasizes the critical need for effective pain management strategies that minimize the risk of adverse side effects(6).
Topical NSAIDs penetrate the skin, reaching the underlying tissues and joints. They inhibit cyclooxygenase (COX) enzymes, reducing prostaglandin production and subsequent pain and inflammation. This localized action minimizes systemic absorption, reducing the risk of adverse effects.
As with any medication, Topical NSAIDs carry risks and contraindications. These include skin irritation, such as redness, itching, and burning. Furthermore, they can elicit allergic reactions and, in rare cases, lead to dermatitis. Finally, clinicians must be cautious when working with patients with a history of hypersensitivity to NSAIDs, asthma, or aspirin exacerbated respiratory disease (AERD) (or Samster’s Triad)(see figure 1)(8).
Aspirin exacerbated respiratory disease is characterized by three primary components: bronchial asthma, nasal polyps, and aspirin intolerance. The pathogenesis is linked to a nonallergic hypersensitivity reaction, particularly an abnormal metabolism of arachidonic acid, leading to an imbalance in the synthesis of eicosanoids such as prostaglandins and leukotrienes. This causes inflammation in the respiratory tract. Clinically, it often begins with nasal symptoms and progresses to asthma and aspirin intolerance over time. Diagnosis typically involves aspirin provocation tests, and management may include aspirin desensitization, especially for patients with recurrent nasal polyps and overdependence on corticosteroids. In addition, patients with AERD may develop life-threatening symptoms, including an asthmatic attack or a special rash, when they take aspirin or nonsteroidal anti-inflammatory medications(8).
Our international team of qualified experts (see above) spend hours poring over scores of technical journals and medical papers that even the most interested professionals don't have time to read.
For 17 years, we've helped hard-working physiotherapists and sports professionals like you, overwhelmed by the vast amount of new research, bring science to their treatment. Sports Injury Bulletin is the ideal resource for practitioners too busy to cull through all the monthly journals to find meaningful and applicable studies.
*includes 3 coaching manuals
Get Inspired
All the latest techniques and approaches
Sports Injury Bulletin brings together a worldwide panel of experts – including physiotherapists, doctors, researchers and sports scientists. Together we deliver everything you need to help your clients avoid – or recover as quickly as possible from – injuries.
We strip away the scientific jargon and deliver you easy-to-follow training exercises, nutrition tips, psychological strategies and recovery programmes and exercises in plain English.